Khalid S Iqbal

US Patent:

8338378, Dec 25, 2012

Filed:

Mar 17, 2008

Appl. No.:

12/531616

Inventors:

Herbert Mossler - Seekirchen, AT
Khalid Iqbal - Staten Island NY, US

Assignee:

Research Foundation For Mental Hygiene, Inc. - Menands NY

International Classification:

A01N 37/18
A61K 38/04

US Classification:

514 177, 514 165, 514 182, 530327, 530328, 530330

Abstract:

The present invention relates to a neurotrophic peptide having an amino acid sequence selected from the group consisting of VGDGGLFEKKL (SEQ ID NO: 1), EDQQVHFTPTEG (SEQ ID NO: 2) and IPENEADGMPATV (SEQ ID NO: 3).

US Patent:

8349577, Jan 8, 2013

Filed:

Apr 23, 2010

Appl. No.:

12/766391

Inventors:

Khalid Iqbal - Staten Island NY, US
Sonia Chalbot - New York NY, US

Assignee:

Research Foundation For Mental Hygiene, Inc. - Menands NY

International Classification:

C12Q 1/34

US Classification:

435 18, 514 177

Abstract:

A system and method for evaluating blood-neural barrier permeability. Phospholipid liposomes are labeled with a fluorescent phospholipase A2 substrate and exposed to cerebrospinal fluid. The change in fluorescence is monitored to determine PLA2 activity. The PLA2 activity is used to evaluate the permeability and function of the blood-neural barrier.

US Patent:

8592374, Nov 26, 2013

Filed:

Mar 9, 2011

Appl. No.:

13/044323

Inventors:

Herbert Mösler - Seekirchen, AT
Khalid Iqbal - Staten Island NY, US

Assignee:

Research Foundation for Mental Hygiene, Inc. - Menands NY

International Classification:

A01N 37/18
A61K 38/04

US Classification:

514 177, 514 165, 514 182, 530327, 530328, 530330

Abstract:

The present invention relates to a neurotrophic peptide having an amino acid sequence of VGDGGLFEKKL (SEQ ID NO:1), EDQQVHFTPTEG (SEQ ID NO:2) or IPENEADGMPATV (SEQ ID NO:3), and comprising an adamantyl group at the C- and/or N-terminal end.

US Patent:

20030165575, Sep 4, 2003

Filed:

Aug 12, 2002

Appl. No.:

10/218182

Inventors:

Khalid Iqbal - Staten Island NY, US

Assignee:

Research Foundation for Mental Hygeine, Inc. - Albany NY

International Classification:

A61K033/32
A61K033/06
A61K038/00

US Classification:

424/639000, 424/682000, 514/002000

Abstract:

The present invention is directed to methods for treating Alzheimer disease and other disorders associated with the presence of neurofibrillary tangles (NFTs) by increasing the activity of a phosphatase towards abnormal hyperphosphorylated tau (“AD P-tau”) present in the NFTs of paired helical filaments in the neurons of patients having Alzheimer disease or other NFT-associated disorder. Pharmaceutical compositions and diagnostic methods are also provided. The inventions provide methods of treatment by administering to a subject a therapeutically effective amount of a composition comprising a molecule which increases protein phosphatase activity toward AD P-tau, a phosphatase which dephosphorylates AD P-tau, or a nucleic acid encoding such a phosphatase.

US Patent:

20040019118, Jan 29, 2004

Filed:

Jul 17, 2003

Appl. No.:

10/622163

Inventors:

Khalid Iqbal - Staten Island NY, US

International Classification:

A61K031/13

US Classification:

514/659000

Abstract:

Aminocyclohexane and aminoalkylcyclohexane compounds, which are systemic-ally-active as NMDA receptor antagonists, are effective in inhibiting abnormal hyperphosphorylation of microtubule associated protein tau, method of treating disorders resulting from or associated with abnormal hyperphosphorylation of microtubule associated protein tau, and pharmaceutical compositions comprising the same.

US Patent:

20060014209, Jan 19, 2006

Filed:

Jul 13, 2004

Appl. No.:

10/890508

Inventors:

Khalid Iqbal - Staten Island NY, US
Michael Flory - New York NY, US

International Classification:

G01N 33/53
G01N 33/537
G01N 33/543

US Classification:

435007100, 435007930

Abstract:

A method for diagnosing distinct subgroups of Alzheimer's Disease, the method comprising the steps of obtaining a sample of cerebrospinal fluid and determining the level of ubiquitin, the level of Aβ, and the level of tau present in the sample. Based on the levels of each composition in the cerebrospinal fluid, the sample can be assigned to distinct subgroups.

US Patent:

20080070263, Mar 20, 2008

Filed:

Aug 14, 2007

Appl. No.:

11/838502

Inventors:

Khalid Iqbal - Staten Island NY, US
Michael Flory - New York NY, US

Assignee:

THE RESEARCH FOUNDATION FOR MENTAL HYGIENE - Albany NY

International Classification:

G01N 33/53

US Classification:

435007800

Abstract:

A method for diagnosing distinct subgroups of Alzheimer's Disease, the method comprising the steps of obtaining a sample of cerebrospinal fluid and determining the level of ubiquitin, the level of Aβ, and the level of tau present in the sample. Based on the levels of each composition in the cerebrospinal fluid, the sample can be assigned to distinct subgroups, thereby allowing for the diagnosis of Alzheimer's Disease or Alzheimer's Disease pathology in the patient from whom the sample was taken.

US Patent:

20090005459, Jan 1, 2009

Filed:

May 12, 2008

Appl. No.:

12/151996

Inventors:

Khalid Iqbal - Staten Island NY, US

International Classification:

A61K 31/13
A61P 25/00

US Classification:

514662

Abstract:

Aminocyclohexane and aminoalkylcyclohexane compounds, which are systemically-active as NMDA receptor antagonists, are effective in inhibiting abnormal hyperphosphorylation of microtubule associated protein tau, method of treating disorders resulting from or associated with abnormal hyperphosphorylation of microtubule associated protein tau, and pharmaceutical compositions comprising the same.